Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.46 |
| ▸ | THPO | P40225 | 3/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.44 |
| ▸ | LMNA | P02545 | 5/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | BLM | P54132 | 3/20 | 0.44 |
| ▸ | GFER | P55789 | 3/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | GMNN | O75496 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14870034 | 1.00 | MAPT (0.46) | MAPTHSD17B10MAPK1HIF1AALOX15 | |
| SCHEMBL22352895 | 1.00 | MAPT (0.46) | MAPTHSD17B10MAPK1HIF1AALOX15 | |
| SCHEMBL14872470 | 0.90 | MAPT (0.46) | MAPTHSD17B10MAPK1HIF1AALOX15 | |
| SCHEMBL14869968 | 0.87 | ALPG (0.46) | MAPTHSD17B10MAPK1HIF1AALOX15 | |
| SCHEMBL14869985 | 0.86 | MAPT (0.50) | MAPTHSD17B10MAPK1HIF1AALOX15 | |
| SCHEMBL15101650 | 0.83 | MAPT (0.42) | MAPTHSD17B10MAPK1HIF1AALOX15 | |
| SCHEMBL14870279 | 0.83 | MAPT (0.42) | MAPTHSD17B10MAPK1HIF1AALOX15 | |
| SCHEMBL14869974 | 0.83 | MAPT (0.43) | MAPTHSD17B10MAPK1HIF1AALOX15 | |
| SCHEMBL14870255 | 0.82 | SIGMAR1 (0.43) | HTR1ATAAR1HTR2AHTR3ASIGMAR1 | |
| SCHEMBL14870275 | 0.81 | TAAR1 (0.41) | HSD17B10MAPK1TSHRLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2941245-B1 | DELAYED-RELEASE COMPOSITION COMPRISING BIGUANIDE | ANJI PHARMACEUTICALS INC (US) | 2024-06-26 | — | — | EP | disclosed |
| US-11759441-B2 | Biguanide compositions and methods of treating metabolic disorders | ANJI PHARMACEUTICALS INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-11759441-B2 | Biguanide compositions and methods of treating metabolic disorders | ANJI PHARMACEUTICALS INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-20230285330-A9 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS | ANJI PHARMACEUTICALS INC. | 2023-09-14 | — | — | US | disclosed |
| US-20230285330-A9 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS | ANJI PHARMACEUTICALS INC. | 2023-09-14 | — | — | US | disclosed |
| US-20220151957-A1 | BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS | ANJI PHARMACEUTICALS INC. | 2022-05-19 | — | — | US | disclosed |
| US-11065215-B2 | Biguanide compositions and methods of treating metabolic disorders | ANJI PHARMA (US) LLC (US) | 2021-07-20 | — | — | US | disclosed |
| US-10668031-B2 | Biguanide compositions and methods of treating metabolic disorders | ANJI PHARMA (US) LLC (US) | 2020-06-02 | — | — | US | disclosed |
| US-20200138751-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | ANJI PHARMACEUTICALS INC. | 2020-05-07 | — | — | US | disclosed |
| US-20190307708-A1 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS | ELCELYX THERAPEUTICS INC (US) | 2019-10-10 | — | — | US | disclosed |
| WO-2014107617-A1 | DELAYED-RELEASE COMPOSITION COMPRISING BIGUANIDE | ELCELYX THERAPEUTICS, INC. (US) | 2014-07-10 | — | — | WO | disclosed |
| US-20140193498-A1 | Compositions and Methods for Treating Metabolic Disorders | ANJI PHARMACEUTICALS INC. | 2014-07-10 | — | — | US | disclosed |
| US-20140193498-A1 | Compositions and Methods for Treating Metabolic Disorders | ANJI PHARMACEUTICALS INC. | 2014-07-10 | — | — | US | disclosed |
| WO-2014011926-A1 | COMPOSITIONS COMPRISING STATINS, BIGUANIDES AND FURTHER AGENTS FOR REDUCING CARDIOMETABOLIC RISK | ELCELYX THERAPEUTICS, INC. (US) | 2014-01-16 | — | — | WO | disclosed |
| US-20130177604-A1 | Compositions and Methods of Treating Metabolic Disorders | ELCELYX THERAPEUTICS, INC. (US) | 2013-07-11 | — | — | US | disclosed |
| US-20130177604-A1 | Compositions and Methods of Treating Metabolic Disorders | ELCELYX THERAPEUTICS, INC. (US) | 2013-07-11 | — | — | US | disclosed |
| WO-2013103384-A1 | BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS | ELCELYX THERAPEUTICS, INC. (US) | 2013-07-11 | — | — | WO | disclosed |
| WO-2013103919-A2 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS | ELCELYX THERAPEUTICS, INC. (US) | 2013-07-11 | — | — | WO | disclosed |
| US-20130095140-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | ELCELYX THERAPEUTICS, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| US-20130095140-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | ELCELYX THERAPEUTICS, INC. (US) | 2013-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10668031-B2 | Biguanide compositions and methods of treating metabolic disorders | SLC5A2, SLC5A1, GPR119 | MAPT 3264/4885HSD17B10 269/4885MAPK1 2738/4885 |
| US-11065215-B2 | Biguanide compositions and methods of treating metabolic disorders | SLC5A2, SLC5A1, GPR119 | MAPT 3264/4885HSD17B10 269/4885MAPK1 2738/4885 |
| US-20130095140-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | SLC5A2, SLC5A1, GPR119 | MAPT 3264/4885HSD17B10 269/4885MAPK1 2738/4885 |
| US-11759441-B2 | Biguanide compositions and methods of treating metabolic disorders | SLC5A2, SLC5A1, GPR119 | MAPT 3264/4885HSD17B10 269/4885MAPK1 2738/4885 |
| US-20130177604-A1 | Compositions and Methods of Treating Metabolic Disorders | FABP2, GPR119, PNLIP | MAPT 3415/4885HSD17B10 585/4885MAPK1 4521/4885 |
| US-20190307708-A1 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS | FABP2, GPR119, PNLIP | MAPT 3252/4885HSD17B10 594/4885MAPK1 4582/4885 |
| US-20140193498-A1 | Compositions and Methods for Treating Metabolic Disorders | SLC5A2, SLC10A1, GPR119 | MAPT 2644/4885HSD17B10 357/4885MAPK1 4417/4885 |
| US-20220151957-A1 | BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS | SLC5A2, SLC5A1, GPR119 | MAPT 3264/4885HSD17B10 269/4885MAPK1 2738/4885 |
| US-20230285330-A9 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS | FABP2, GPR119, PNLIP | MAPT 3252/4885HSD17B10 594/4885MAPK1 4582/4885 |
| US-20200138751-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | SLC5A2, SLC5A1, GCG | MAPT 3212/4885HSD17B10 290/4885MAPK1 2604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.